Clinical Trial Update: Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating duloxetine with neurofeedback training for chemotherapy-induced peripheral neuropathy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy
• Hematologic Malignancy
• Solid Malignant Neoplasm

Drugs mentioned

• Duloxetine (DULOXETINE)
• Neurofeedback Training

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Status: RECRUITING